Recent News about Valitor:
February 1, 2019
Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised over $2.5MM in funding for the continued development of our lead products. As a part of this deal, Walter Moos and Drew Lanza were appointed to our Board of Directors, and we are excited to add their experience as entrepreneurs and investors to the Valitor leadership team.
September 13, 2018
Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provide sustained immune cell activation after intratumoral injection. Specifically, we will generate a therapeutic product that can be used to generate a system-wide immune response against metastatic melanomas cells after administration to only a subset of surface-accessible lesions.
September 11, 2018
Valitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will continue the development of a long-acting anti-inflammatory product that is designed for intra-articular administration. Specifically, we will evaluate the efficacy of our drug to prevent post-traumatic osteoarthritis following joint injuries
August 1, 2018
Valitor has recruited and hired Amy Twite, PhD to join our team as Director Chemistry. Amy graduated from UC Berkeley’s College of Chemistry with extensive experience in conjugation chemistry and cell biology. She has previously headed the chemistry efforts at two early-stage biotech companies. At Valitor, she will be applying her chemistry process development experiment to initiate the manufacturing program for our lead product.
April 30, 2018
Valitor presented the its latest preclinical data at the 2018 Association for Research in Vision and Ophthalmology conference in Honolulu, HI. This report demonstrated a substantial increase in intravitreal half-life for our lead Anti-VEGF compound compared to the drugs that currently approved or in Phase III clinical trials. These results show the clear clinical benefits our products can offer for drugs that are used to treat ocular neovascular diseases.
April 4, 2018
Valitor was among a select group of early-stage start up companies that were invited to participate in the 2018 QB3 Biotech Pitch Summit. This was an exciting opportunity to share Valitor’s science and business plan to top-tier life science investors from around the world. This event was the kick-off of our Series A fundraising, and we were thrilled but the positive reception we received from potential investors.
March 10, 2018
Valitor presented the its first preclinical data demonstration the potential of our anti-inflammatory product to treat arthritis at the Orthopaedic Research Society conference in New Orleans, LA. This report demonstrated a substantial increase intra-articular half-life for our lead anti-inflammatory compound compared an equivalent unconjugated antibody. These data demonstrate how our technology to enhance the ability of anti-inflammatory antibodies to treat a variety of joint disorders.
February 1, 2018
Valitor is proud to announce that we have received a seed investment from The House Fund. These funds will augment our current SBIR funding by accelerating the commercialization of our lead therapeutic product for indications in ophthalmology.